Blog
RSS FeedPosted by Michael Wonder on 15 Feb 2016
Alirocumab hypercholesterolemia or mixed dyslipidaemia: additional benefits not covered says IQWiG
15 February 2016 - An additional benefit compared to the appropriate comparator therapies has not been established for this substance because ...
Posted by Michael Wonder on 08 Feb 2016
February 2016 SMC decisions news release
8 February 2016 - SMC accepts treatments for breast cancer, myeloma and ADHD. ...
Posted by Michael Wonder on 08 Feb 2016
NICE issues draft guidance on alirocumab for lipid disorder
8 February 2016 - NICE has published draft guidance not recommending alirocumab (Praluent, Sanofi/Regeneron) as an option for people with high ...
Posted by Michael Wonder on 05 Feb 2016
PHARMAC decision relating to filgrastim and methotrexate pre-filled syringes
5 February 2016 - PHARMAC is pleased to announce the approval of an agreement with Novartis New Zealand Ltd. involving filgrastim, ...
Posted by Michael Wonder on 03 Feb 2016
PHARMAC decision to widen access to budesonide with eformoterol (Symbicort Turbuhaler and Vannair)
3 February 2016 - From 1 March 2016, the effect of the decision is that: ...
Posted by Michael Wonder on 03 Feb 2016
PHARMAC decision relating to a number of respiratory products
3 February 2016 - PHARMAC is pleased to announce the approval of agreements with Boehringer Ingleheim and GlaxoSmithKline involving a number ...
Posted by Michael Wonder on 01 Feb 2016
Viacoram now approved in Canada as a new first-line treatment in hypertension
29 January 2016 - Viacoram (perindopril arginine with amlodipine besylate) has received approval by Health Canada as a first line ...
Posted by Michael Wonder on 30 Jan 2016
First specific replacement therapy to treat rare bleeding disorder
29 January 2016 - Coagadex recommended for approval for prevention of bleeding episodes for patients with factor X deficiency. ...
Posted by Michael Wonder on 30 Jan 2016
EMA fast-tracks treatment of multiple myeloma for approval in EU
29 January 2016 - Empliciti is a monoclonal antibody that works by activating the body’s immune system to attack and kill ...
Posted by Michael Wonder on 29 Jan 2016
Health Canada approves Amgen's new multiple myeloma treatment Kyprolis (carfilzomib)
28 January 2016 - Amgen Canada Inc. today announced that Health Canada has approved Kyprolis (carfilzomib) in combination with lenalidomide and ...
Posted by Michael Wonder on 28 Jan 2016
FDA approves first drug to show survival benefit in liposarcoma
28 January 2016 - The U.S. FDA today approved Halaven (eribulin mesylate) for the treatment of liposarcoma (a specific type of ...
Posted by Michael Wonder on 27 Jan 2016
Health Canada approves PrOrkambi (lumacaftor/ivacaftor) - the first medicine to treat the underlying cause of cystic fibrosis for people ages 12 and older with two copies of the F508del mutation
26 January 2016 - Approximately 1,500 people in Canada are ages 12 and older and have two copies of the F508del ...
Posted by Michael Wonder on 27 Jan 2016
NICE publishes final drug recommendations for 5 separate medical conditions
27 January 2016 - Each piece of guidance looked at the cost-effectiveness of a particular drug to treat a specific medical ...
Posted by Michael Wonder on 26 Jan 2016
NICE issues final guidance recommending 7 drugs for rheumatoid arthritis
26 January 2016 - In final updated guidance published today NICE recommends a number of drugs called biological disease modifying drugs ...
Posted by Michael Wonder on 23 Jan 2016
NICE draft guidance recommends nivolumab for advanced skin cancer
22 January 2016 - The independent Committee decided that a consultation on the draft recommendations was not needed for this appraisal, ...